OUR RESEARCH
MASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
OUR RESEARCH
MASH
Targets & Clinical Progress
Posters/Publications
OUR PIPELINE
Pipeline
Clinical Trials
Expanded Access Policy
OUR STORY
Overview
Management Team
Partnership
NEWS
CAREERS
News
2024
2023
2022
2021
2020
2019
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
17/06/2020
Ascletis’ THR-beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
13/05/2020
Ascletis’ IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
18/02/2020
